BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. Cox earned a Master of Business Administration with concentrations in accounting, finance and economics from the University of Chicago Booth School of Business and a Bachelor of Business Administration in finance from the University of Notre Dame.Horizon Therapeutics plc is an Ireland-based global biotechnology company. Cox was vice president, capital markets at BMO Capital Markets and held investment banking roles at JMP Securities and Stout.īrowse The Complete News About Fintech : FintechOS Updates Platform to Boost the Productivity of Financial Technology ![]() Cox also previously spent time on Horizon’s business development team, where he supported multiple acquisitions, financings and licensing transactions. Additionally, he leads capital markets activities and oversees Horizon’s global real estate, security and facilities functions. Walbert, where he had responsibilities spanning financial planning, corporate strategy, mergers and acquisitions, acquisition integration and corporate project management. Cox joined Horizon in 2016 and has served in various roles across business development and corporate development, including most recently as senior vice president, corporate development and chief of staff to Mr. Get In-Depth Insights of Fintech : Barclays US Consumer Bank Commits $1 Million to Delaware State University to Advance Pathways to an Inclusive Economy in Underserved Communities His experience at Horizon and his deep financial knowledge will be essential in continuing to drive our long-term strategy.” Additionally, he has been a leader in many of our major strategic efforts, including the Viela Bio acquisition. Walbert continued, “Aaron has been deeply involved in key aspects of our business during the last five years, including leading our capital markets activities. Read More About Fintech News : Broadridge Upgrades International Post-Trade Client Onboarding Using PeerNova’s Data Quality SaaS Platform I would like to thank him for his leadership as well as his dedication and commitment to Horizon’s mission.” “He has built a strong finance team during his tenure and has been a valued partner to me and Horizon’s board of directors. “Paul has served as Horizon’s CFO since 2014 and has been critical in guiding and driving our growth,” said Tim Walbert, chairman, president and chief executive officer, Horizon. ![]() Aaron Cox, who was named executive vice president, finance, will succeed Mr. ![]() Horizon Therapeutics plc announced Paul Hoelscher, executive vice president, chief financial officer, and continue as an advisor to the Company through May 2023.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |